Zhitong Finance APP News3xshimanoultegra14000xtd, Zhongguancun (000931)(0009313xshimanoultegra14000xtd.SZ) announced that Duoduo Pharmaceutical Co., Ltd.(referred to as Duoduo Pharmaceutical), a subsidiary of the company, recently received the "Acceptance Notice" issued by the State Food and Drug Administration for the drug registration application of the chemical generic drug Ambroxol Hydrochloride Injection.
Duoduo Pharmaceutical's Ambroxol Hydrochloride Injection (specification 2ml: 15mg) was established and developed in 2021. Its indications are: suitable for acute and chronic lung diseases accompanied by abnormal sputum secretion and poor sputum discharge function, such as expectorant treatment of acute exacerbations of chronic bronchitis, wheezing bronchitis and bronchial asthma; preventive treatment of pulmonary complications after surgery; and treatment of infant respiratory distress syndrome (IRDS) in premature infants and newborns.
